New Academy gives Irish researchers a voice in policy making

Tuesday, February 14, 2012 11:46 AM

The European Commissioner for Research, Innovation and Science, Máire Geoghegan-Quinn, has launched a new Academy to bring together Ireland's leading medical researchers to promote excellence in biomedical research, with the ultimate aim of improving the health of the population.

The Irish Academy of Medical Sciences (IAMS) will draw on the knowledge of Ireland's top medical scientists to provide an independent resource of expertise on complex issued related to medical science and ethics to ensure a coherent and integrated policy on health research at a national and international level.

The Royal College of Surgeons in Ireland (RCSI) academics Professor Orla Hardiman, Professor Brian Harvey, Professor Elaine Kay, Professor Gerry McElvaney and Professor Jochen Prehn are among the founding Fellows of the Academy.

Until now, Ireland was one of the few European countries with no established body to represent its medical researchers in this way. IAMS will allow Ireland to actively participate in medical sciences interchanges at the European level. The Academy will partner with state agencies and industry as an independent resource of expertise in medical science and healthcare.

"I welcome the formation of the new Academy, which harnesses the significant expertise that already exists within Irish academic medicine,” said Commissioner Geoghegan-Quinn. “Excellence in research ultimately leads to excellent care for patients. The strategic partnerships that will arise from the establishment of the Academy will contribute to building a knowledge-based economy, sustainable employment opportunities for Irish graduates and the overall improvement of Irish society and its healthcare system. I congratulate the founding Council of IAMS for this important initiative, which I am confident will ensure Ireland's position at the forefront of biomedical research into the future."

To coincide with the launch, the Academy published its first position paper on the future direction for biomedical research in Ireland. Among the issues highlighted is the importance of sustainable funding for biomedical research.

"While the level of investment in biomedical research in Ireland increased substantially during the boom years, it is essential that this momentum be maintained,” said Professor Dermot Kelleher, Honorary President, Irish Academy of Medical Sciences. “In terms of developing the key industry relationships for the knowledge economy, it is critical that the infrastructure in our teaching hospitals is seen as a source of real academic strength in terms of expertise and capacity in clinical research."

He continued, "Investing in publicly-funded biomedical research, and in particular clinically-based research, will lead to significant economic benefit, job creation, added value to the knowledge economy and individual and societal gain for Ireland. It will also assure the development and retention of the brightest research capacity and capability in the country."  

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs